Limited Competition for the Continuation of Rare Diseases Clinical Research Consortia in the Rare Diseases Clinical Research Network (U54)

The summary for the Limited Competition for the Continuation of Rare Diseases Clinical Research Consortia in the Rare Diseases Clinical Research Network (U54) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition for the Continuation of Rare Diseases Clinical Research Consortia in the Rare Diseases Clinical Research Network (U54): The purpose of this limited competition Funding Opportunity Announcement (FOA) is to provide an opportunity for the NINDS American Recovery and Reinvestment Act (ARRA)-funded consortia to compete for another three years of participation in the Rare Diseases Clinical Research Network (RDCRN). The RDCRN is a collaborative and coordinated network of Clinical Research Consortia comprised of investigators and patient support groups committed to investigation of rare diseases working in partnership with the Data Management Coordinating Center to enhance communication and sharing of resources in a multidisciplinary approach. The RDCRN is focused on 1) the collection of clinical information to better define disease natural history and to develop biomarkers as well as new approaches to diagnosis, prevention, and treatment of rare diseases, and 2) training of new clinical investigators in rare diseases research.